Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

February 2022 | 75 pages | ID: F626EAC3F796EN
Global Markets Direct

Abstracts

Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis, or lupus. Treatment includes pain relievers, antidepressants, and anti-seizure drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 10, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Fibromyalgia (Fibromyalgia Syndrome) - Overview
Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibromyalgia (Fibromyalgia Syndrome) - Companies Involved in Therapeutics Development
Aardvark Therapeutics Inc
Aptinyx Inc
Cortene Inc
Engrail Therapeutics Inc
Epitech Group SpA
H. Lundbeck AS
Imbrium Therapeutics LP
Indaptus Therapeutics Inc
Luye Pharma Group Ltd
One World Cannabis Ltd
PRISM Pharma Co Ltd
Reven Holdings Inc
Shanghai Lvdao Pharmaceutical Technology Co Ltd
Statera Biopharma Inc
Tetra Bio-Pharma Inc
Teva Pharmaceutical Industries Ltd
Tonix Pharmaceuticals Holding Corp
Tryp Therapeutics Inc
Virios Therapeutics, Inc
Fibromyalgia (Fibromyalgia Syndrome) - Drug Profiles
(celecoxib + famciclovir) - Drug Profile
Product Description
Mechanism Of Action
History of Events
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
CT-38 - Drug Profile
Product Description
Mechanism Of Action
dronabinol - Drug Profile
Product Description
Mechanism Of Action
History of Events
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
LD-04185 - Drug Profile
Product Description
Mechanism Of Action
LuAG-06466 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-03012 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MS-11 - Drug Profile
Product Description
Mechanism Of Action
naltrexone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
NP-013 - Drug Profile
Product Description
Mechanism Of Action
NYX-2925 - Drug Profile
Product Description
Mechanism Of Action
History of Events
palmidrol - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
PPP-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
psilocybin - Drug Profile
Product Description
Mechanism Of Action
RPOT-1002a - Drug Profile
Product Description
Mechanism Of Action
Small Molecule 1 to Agonize CB1 and CB2 for Chronic Pain and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Agonize CB1 and CB2 for Fibromyalgia and Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
History of Events
sunobinop tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
TNX-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRP-8803 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Type 1 Diabetes and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects
Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products
Fibromyalgia (Fibromyalgia Syndrome) - Product Development Milestones
Featured News & Press Releases
Feb 09, 2022: Aptinyx hosts virtual portfolio review event to showcase NYX-2925 in chronic pain
Dec 03, 2021: Tryp Therapeutics to present at the H.C. Wainwright Psychedelics Conference on December 6, 2021
Dec 02, 2021: Tryp Therapeutics receives confirmation from FDA to proceed with phase 2a study in fibromyalgia
Dec 01, 2021: Virios Therapeutics achieves over 50% enrollment milestone in its phase 2b clinical trial for fibromyalgia
Nov 08, 2021: Tonix Pharmaceuticals presents positive results from phase 3 relief study of TNX-102 SL for the management of fibromyalgia at the American College of Rheumatology Convergence 2021
Sep 27, 2021: Tonix Pharmaceuticals announces oral presentation at the American College of Rheumatology Convergence 2021
Aug 16, 2021: Virios Therapeutics CEO highlights novel therapeutic approach for treating fibromyalgia and irritable bowel syndrome in Stock News now video interview
Jul 26, 2021: Virios Therapeutics highlights clinical sites fully operational in phase 2b fibromyalgia study featuring FDA “Fast Track” review designated antiviral therapy, oral IMC-1
Jun 09, 2021: Virios Therapeutics highlights safety data from phase 2a fibromyalgia trial at the International Association for the Study of Pain (IASP) World Congress
Jun 04, 2021: Virios Therapeutics announces dosing of first patient in phase 2b trial evaluating IMC-1 in patients with fibromyalgia
Jun 03, 2021: Tonix Pharmaceuticals presents positive results from phase 3 relief study of TNX-102 SL for the management of fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Jun 02, 2021: Virios Therapeutics presents phase 2a Fibromyalgia trial data on efficacy analyses of key secondary endpoints at the EULAR European Congress of Rheumatology
May 26, 2021: Tonix Pharmaceuticals announces presentation of two posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 24, 2021: Virios Therapeutics announces oral presentation of clinical data at Digestive Disease Week (DDW)
May 10, 2021: Tryp Therapeutics partners with Clinlogix for clinical trial support
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aardvark Therapeutics Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aptinyx Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Cortene Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Engrail Therapeutics Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Epitech Group SpA, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by H. Lundbeck AS, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Imbrium Therapeutics LP, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Indaptus Therapeutics Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Luye Pharma Group Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by One World Cannabis Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by PRISM Pharma Co Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Reven Holdings Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Shanghai Lvdao Pharmaceutical Technology Co Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Statera Biopharma Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tetra Bio-Pharma Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tryp Therapeutics Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Virios Therapeutics, Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, 2022 (Contd..1)
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, 2022 (Contd..2)
Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022